Overview
DiaCarta provides highly sensitive qPCR-based assays and technologies like XNA clamping and SuperbDNA for detecting rare mutations in oncology, including lung, colorectal, bladder, and pan-cancer panels. Their solutions support liquid biopsy, FFPE samples, and work on existing lab instruments for rapid, cost-effective diagnostics. They offer CLIA-certified services and research-use-only testing for precision medicine applications.
Frequently asked questions
- What technologies does DiaCarta offer for mutation detection?
- DiaCarta offers XNA molecular clamp technology for ultrasensitive qPCR assays detecting mutations down to 0.1% LoD, SuperbDNA for signal amplification, and DigiPlex for multiplexing proteins and DNA.
- What cancer assays are available from DiaCarta?
- DiaCarta provides QClamp kits for KRAS, NRAS, EGFR, BRAF, PIK3CA, JAK2, c-KIT mutations, plus multiplex panels like ColoScape for colorectal cancer, and assays for bladder, pan-cancer, cervical, head and neck cancers.
- Does DiaCarta offer CLIA-certified services and global support?
- Yes, DiaCarta operates a CLIA-certified lab with expertise in genomic testing for clinical trials, supporting global operations and high-quality certifications for precision diagnostics.